Quanterix’ Ultra-Sensitive Simoa Technology Demonstrates Promise for COVID-19 Acute Care, Immune Response Monitoring and Treatment
“Bringing together the top global frontline physicians and thought leaders from the hot zones in the infectious disease field to exchange ideas and best practices for COVID-19 research and patient studies is invaluable in the current war against COVID-19 and protection against future pandemics,” said
The inaugural webinar, “Highly Sensitive Multiplex Test to Monitor the Immune Response to Viral Infection,” provided an orientation of the disruptive Simoa® technology, featured insights from several researchers actively researching COVID-19 patients in
Together, these collaborators are exploring ways to optimize surveillance of immune response to SARS-CoV-2 by measuring key cytokines and chemokines with sensitivity and precision. Emerging research suggests that tools for assessing Type I interferon (IFN-α), which is considered to be one of the earliest indicators of risk for deregulation of the inflammatory response and cytokine storm, and IL-6 and several other pro-inflammatory biomarkers are among the most pressing. Various collaborations are underway to deploy existing Simoa cytokine assay panels to study COVID-19, some of which can detect up to 10 different cytokines simultaneously. These partnerships also seek to evolve new assays with augmented multiplexed capabilities for more granular stratification of cytokine levels in patients and measure critical biomarkers of damage to neurological and cardiovascular systems.
The company is also investigating the potential to apply the unrivaled sensitivity of its Simoa technology to SARS-Cov-2 antibody detection. Heralded as one of the most promising strategies for true containment of COVID-19, antibody tests are being developed at breakneck speeds. Serological antibody testing can provide information about true prevalence of COVID-19, enable ‘return-to-work’ paradigm, and serve as a complementary tool for diagnosis, alongside viral detection methods. There is opportunity to expand the reach and impact of Simoa technology into early viral antigen detection and serology testing. Simoa’s ultra-sensitive testing platforms could also be explored as a way to generate reliable results from less invasive testing, such as dried blood spots, nasal swabs and saliva-based tests.
Learn more about how you can get involved with
Further details on Quanterix’ infectious disease offerings and educational resources can be accessed here: https://www.quanterix.com/therapeutic-areas/infectious-disease.
For more information on
Details on the company’s homebrew services for developing customer Simoa assays are available here: https://www.quanterix.com/products-technology/homebrew.
COVID-19 investigators with questions about Simoa or who are in need of testing support are encouraged to contact our team at: https://www.quanterix.com/contact.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20200410005190/en/
Media:
quanterix@pancomm.com
Investor Relations:
(774) 278-0496
shrusovsky@quanterix.com
Source: